A US government advisory committee on Wednesday unanimously voted to urge the Food and Drug Administration to approve a new drug made by Merck to fight hepatitis C, a disease which attacks the liver.
Apr 27, 2011
5 / 5 (1)
0
Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant ...
Apr 02, 2011
not rated yet
0
Data presented at the International Liver Congress highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance ...
Apr 02, 2011
not rated yet
0
Berlin, Germany, Friday 1st April 2011: Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help ...
Apr 01, 2011
5 / 5 (1)
0
The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.
Sep 02, 2010
not rated yet
0
Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the ...
Aug 08, 2010
5 / 5 (3)
0
Researchers from Denmark, Sweden, Norway and Finland (the NORDynamIC project group) have observed that depressive symptoms in patients with hepatitis C virus (HCV) infection are commonly overlooked in routine clinical interviews, ...
Jul 20, 2010
not rated yet
0
The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.
May 14, 2010
not rated yet
0
A recent study confirms that the standard hepatitis C (HCV) therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared ...
Mar 25, 2010
not rated yet
0
The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of ...
Apr 30, 2009
1 / 5 (1)
0
